Clinical Trial Update: Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase III open-label trial evaluating first-line osimertinib with or without datopotamab deruxtecan for EGFR-mutant locally advanced or metastatic non-small cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Datopotamab Deruxtecan (Dato-DXd) (datopotamab deruxtecan)
• Osimertinib (Tagrisso) (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: RECRUITING